Welichem Biotech Inc.

Developing and commercializing new therapeutics for autoimmune/ inflammatory diseases and cancer
Producing better therapeutics based on a novel source of compounds from symbiotic microorganisms
Unique compounds discovered by Welichem principals, leading scientists in symbiotic microorganisms, through more than 25 years of research

Compounds have exceptionally effective bioactivities - immunomodulation & anti-proliferative.
Existing evidence shows high efficacy with low or no toxicity
Compounds originate from natural process that has existed for millions of years – less likelihood of unknowns to occur through clinical trials
Pipeline of other ultra high quality drug leads – technology has already yielded many bioactive, small molecules in over 10 different classes of chemicals that exhibit a range of anti-inflammatory, antimicrobial and anti-proliferative (i.e. anti-cancer and anti-psoriatic) bioactivities

First drug candidate, WBI-1001, has successfully completed a phase I clinical trial for psoriasis, and a phase IIa clinical trial for atopic dermatitis (a form of eczema)
Second drug candidate, WBI-2100, is currently undergoing pre-clinical studies

Compared with existing drugs, Welichem’s therapeutics offer the potential of safer treatments with greater efficacy and faster relief.

Complete phase II clinical trials on WBI-1001
Enter into an agreement with a major biotech or pharmaceutical company for co-development, or
Out-license key compound for upfront and milestone payments, and royalties after receiving marketing approval